TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26997579

Group type: EXPERIMENTAL
Intervention: APF530 500 mg subcutaneously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron 0.15 mg/kg intravenously
Number of subjects: 0
Study: 25329446

Group type: EXPERIMENTAL
Intervention: Early presence and high abundance of Moraxella and Corynebacterium/Dolosigranulum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High abundance of Haemophilus or Streptococcus
Number of subjects: 60
Study: 22427029

Group type: EXPERIMENTAL
Intervention: Cotton pledget packing with 4% lignocaine and xylometazoline nasal drops
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical spray with 10% lignocaine and xylometazoline drops
Number of subjects: 100
Study: 19434508

Group type: EXPERIMENTAL
Intervention: Immediate feedback in an intelligent tutoring system (ITS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Other metacognitive scaffolds
Number of subjects: 23
Study: 18407376

Group type: EXPERIMENTAL
Intervention: Standardized volume/weight-based dose reformulation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Broselow Pediatric Emergency Tape
Number of subjects: 16
Study: 15690654

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch (n = 36)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Side-to-end anastomosis (n = 35)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 12529662

Group type: EXPERIMENTAL
Intervention: High CD34% in PBSC products (>0.8% CD34+ cells)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Low CD34% in PBSC products (<=0.8% CD34+ cells)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All patients evaluable
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High CD34% in PBSC products
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Hypoplasia period after induction therapy
Number of subjects: 71
Study: 10462235

Group type: EXPERIMENTAL
Intervention: Acellular pertussis (aP) vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 8690109

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GNRH‐a) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1750588

Group type: EXPERIMENTAL
Intervention: 120 mg dihydrocodeine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 90 mg dihydrocodeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17152744

Group type: EXPERIMENTAL
Intervention: Luteinising hormone releasing hormone (100 microg, i.v.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thyrotropin (TSH) releasing hormone (200 microg, i.v.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Regular insulin (.1 U/kg, i.v.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PRL response in female series
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Periodic analysis of PRL secretion in male patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study: 31548349

Group type: EXPERIMENTAL
Intervention: Higher plasma 25(OH)D levels (top quintile ≥24.1 ng/mL)
Number of subjects: 1041
Study: 29228929

Group type: EXPERIMENTAL
Intervention: VBN-assisted group
Number of subjects: 140

Group type: COMPARATOR
Intervention: XRF-assisted group
Number of subjects: 140
Study: 26179619

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8mg (dose escalated from 0.6 and 1.2mg/day for 1 week each)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 24385549

Group type: EXPERIMENTAL
Intervention: Weak sense of coherence (SOC)
Number of subjects: 12024

Group type: COMPARATOR
Intervention: Intermediate sense of coherence (SOC)
Number of subjects: 12024

Group type: COMPARATOR
Intervention: Strong sense of coherence (SOC)
Number of subjects: 12024
Study: 21926065

Group type: EXPERIMENTAL
Intervention: 48-hour training program for community health workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training program implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-deployment training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervision by social workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient encounters
Number of subjects: 0
Study: 19540671

Group type: EXPERIMENTAL
Intervention: 1% lidocaine injections
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 50
Study: 17468774

Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic therapy (cefepime administered when neutropenia developed)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Pre-emptive antibiotic therapy (cefepime)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Empiric antibiotic therapy (cefepime administered at onset of fever and neutropenia)
Number of subjects: 153
Study: 15237062

Group type: EXPERIMENTAL
Intervention: Adolescent priming with alcohol self-assessment just prior to check-up (Group II)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Adolescent priming and provider prompting with adolescent self-assessment and brochure (Group III)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Usual care (Group I)
Number of subjects: 409
Study: 15692472

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 568

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 568
Study: 10319538

Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 8733040

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study: 1684991

Group type: EXPERIMENTAL
Intervention: PPA/B (75 mg phenylpropanolamine and 12 mg brompheniramine)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7139401

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg . kg‐1
Number of subjects: 48

Group type: COMPARATOR
Intervention: alfathesin 75 microliters . kg‐1
Number of subjects: 48
Study: 31056710

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus nicotine lozenge
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Nicotine patch alone
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1067
Study: 30280326

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with carbopol (CPc)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide with natrosol (CPn)
Number of subjects: 70
Study: 29362766

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Calorie restriction plus fish oil supplementation (CRF)
Number of subjects: 75
Study: 26444330

Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT - 660 nm, 30 mW, continuous regime, fluency of 10J/cm2) with orthoses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orthoses alone
Number of subjects: 30
Study: 24517339

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2313
Study: 21551082

Group type: EXPERIMENTAL
Intervention: ABI <0.9
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: ABI >1.3
Number of subjects: 219

Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 219
Study: 19946118

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell (BMC) transfer
Number of subjects: 56
Study: 17599484

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 3610

Group type: COMPARATOR
Intervention: No coronary artery bypass grafting (control)
Number of subjects: 3610
Study: 16139175

Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Haloperidol (up to 8 mg/day)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 302
Study: 11851663

Group type: EXPERIMENTAL
Intervention: Suture repair
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Autodermal skin graft
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Onlay polypropylene mesh repair
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 10223219

Group type: EXPERIMENTAL
Intervention: Sticking plaster treatment
Number of subjects: 57

Group type: COMPARATOR
Intervention: Epilation (Control)
Number of subjects: 57
Study: 7595911

Group type: EXPERIMENTAL
Intervention: Nitrendipine (27.3 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mefruside (30.7 mg daily)
Number of subjects: 22
Study: 30837600

Group type: EXPERIMENTAL
Intervention: Weight loss and regain (diet group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 30514841

Group type: EXPERIMENTAL
Intervention: Ethnically diverse papers
Number of subjects: 6000000

Group type: EXPERIMENTAL
Intervention: Ethnically diverse scientists
Number of subjects: 6000000
Study: 26767505

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily for 24 weeks combined with NB-UVB
Number of subjects: 120

Group type: COMPARATOR
Intervention: NB-UVB monotherapy
Number of subjects: 120
Study: 25185628

Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PFPT) biweekly until 12 weeks postoperatively
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care (physician assessment alone)
Number of subjects: 49
Study: 23059199

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (started at study entry)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (started when CD4 percentage declined to less than 15%)
Number of subjects: 300
Study: 19570887

Group type: EXPERIMENTAL
Intervention: 3.86% peritoneal equilibration test (PET)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2.27% peritoneal equilibration test (PET)
Number of subjects: 90
Study: 17215629

Group type: EXPERIMENTAL
Intervention: Qi gong training (16-week medically assisted program)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 43
Study: 15570025

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (26 +/- 5 g soy protein containing 44 +/- 8 mg isoflavones/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Soy protein isolate + probiotic capsules (10^9 colony-forming units Lactobacillus acidophilus DDS-1 and Bifidobacterium longum)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Milk protein isolate (26 +/- 5 g milk protein/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Milk protein isolate + probiotic
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Soy treatments in hypercholesterolemic women (TC > 5.17 mmol/L)
Number of subjects: 37
Study: 11482548

Group type: EXPERIMENTAL
Intervention: Creatine (3x5 g x day(-1))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Iso-nitrogenated placebo (3x10 g x day(-1))
Number of subjects: 42
Study: 9773719

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 7919354

Group type: EXPERIMENTAL
Intervention: 150 mg/m2 busulfan
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4 mg/kg busulfan
Number of subjects: 22
Study: 2448408

Group type: EXPERIMENTAL
Intervention: Conjugated oral estrogens (0.625 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Conjugated oral estrogens (1.25 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (25 micrograms/24 hr)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (50 micrograms/24 hr)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (100 micrograms/24 hr)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Transdermally administered estradiol (200 micrograms/24 hr)
Number of subjects: 23
Study: 31832733

Group type: EXPERIMENTAL
Intervention: Rhinoplasty surgery
Number of subjects: 100
Study: 30478263

Group type: EXPERIMENTAL
Intervention: Controlled seizures
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Seizure attacks 1-5 times
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Seizure attacks 6-10 times
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Seizure attacks greater than 10 times
Number of subjects: 270

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 270

Group type: COMPARATOR
Intervention: Negative medication belief
Number of subjects: 270

Group type: COMPARATOR
Intervention: Low medication adherence
Number of subjects: 270

Group type: COMPARATOR
Intervention: Presence of comorbidities
Number of subjects: 270
Study: 28677237

Group type: EXPERIMENTAL
Intervention: Topical Vitamin B12-barrier cream (MB12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard glycerol-petrolatum-based emollient cream (GPC)
Number of subjects: 22
Study: 26511956

Group type: EXPERIMENTAL
Intervention: Motavizumab (15 mg/kg, five monthly intramuscular doses)
Number of subjects: 2127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127

Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 2127
Study: 24386076

Group type: EXPERIMENTAL
Intervention: Initial colposcopy with biopsies and/or subsequent treatment based on colposcopic and histological findings (n = 1696)
Number of subjects: 3399

Group type: COMPARATOR
Intervention: Cytological surveillance (six-monthly tests; n = 1703)
Number of subjects: 3399

Group type: EXPERIMENTAL
Intervention: Initial colposcopy
Number of subjects: 3399

Group type: COMPARATOR
Intervention: Cytological surveillance
Number of subjects: 3399
Study: 21228029

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (3.5 mg/kg cumulative dose over 96 weeks)
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (5.25 mg/kg cumulative dose over 96 weeks)
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1326
Study: 18224269

Group type: EXPERIMENTAL
Intervention: Calcium + 20 microg (800 IU) vitamin D3
Number of subjects: 208

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both groups (calcium alone and calcium + vitamin D3)
Number of subjects: 208
Study: 16858241

Group type: EXPERIMENTAL
Intervention: Nurse-led education programme, facilitated telephone communication and follow-up visits with an internist at 15 days, 1 and 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care group (follow-up by their primary care physician)
Number of subjects: 200
Study: 12895265

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) for 1 year
Number of subjects: 191

Group type: COMPARATOR
Intervention: Interferon alpha (IFN alpha)-2b for 1 year
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha)-2b + ribavirin (1-1.2 g/day) at the end of treatment
Number of subjects: 191

Group type: COMPARATOR
Intervention: Interferon alpha (IFN alpha)-2b at the end of treatment
Number of subjects: 191
Study: 10646156

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% drops for anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sublingual lorazepam 1 mg before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No sublingual lorazepam
Number of subjects: 100
Study: 9015118

Group type: EXPERIMENTAL
Intervention: Rota colostrum (20 ml for 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rota colostrum (every other day)
Number of subjects: 20
Study: 1825857

Group type: EXPERIMENTAL
Intervention: Atriopeptin III (AP‐3) 0.1 micrograms/kg/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 38
Study: 6626699

Group type: EXPERIMENTAL
Intervention: Methylprednisolone capsule (1 g)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Methylprednisolone suspension (1 g)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous administration of methylprednisolone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-dose pulse therapy
Number of subjects: 4
Study: 29516771

Group type: EXPERIMENTAL
Intervention: Manualised ADL retraining following errorless and procedural learning principles during PTA
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Manualised ADL retraining
Number of subjects: 49
Study: 29248390

Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in suburban schools
Number of subjects: 17650

Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in urban schools
Number of subjects: 17650

Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in suburban settings
Number of subjects: 17650

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 17650
Study: 26919191

Group type: EXPERIMENTAL
Intervention: Robot-assisted ventral mesh rectopexy (RVMR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 30
Study: 25065424

Group type: EXPERIMENTAL
Intervention: Ketamine 8 mg·kg(‐1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 μg·kg(‐1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 4 μg·kg(‐1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 5 μg·kg(‐1)
Number of subjects: 112
Study: 22747316

Group type: EXPERIMENTAL
Intervention: $5 incentive for each name and valid address or phone number
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: $20 incentive for each completed mammogram
Number of subjects: 2968

Group type: COMPARATOR
Intervention: No financial incentive for nomination
Number of subjects: 2968
Study: 20923996

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily or 30 mg twice daily)
Number of subjects: 18405
Study: 17919551

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 3 weeks before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15565083

Group type: EXPERIMENTAL
Intervention: Food For Heart Program (dietary counseling visits)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 175
Study: 11226788

Group type: EXPERIMENTAL
Intervention: Foldable hydrophobic acrylic IOL (AcrySof, Alcon)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Heparin-surface-modified (HSM) PMMA IOL (811C, Pharmacia)
Number of subjects: 62
Study: 10806662

Group type: EXPERIMENTAL
Intervention: Metformin (oral administration for 8-12 weeks)
Number of subjects: 23
Study: 8282323

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg/d) treatment with ad libitum diet
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg/d) with a 150 mmol/24 h sodium diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo with a 150 mmol/24 h sodium diet
Number of subjects: 11
Study: 2917417

Group type: EXPERIMENTAL
Intervention: Intravelar veloplasty (IVV)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control procedure (non-IVV)
Number of subjects: 51
Study: 179286

Group type: EXPERIMENTAL
Intervention: Nicotinic acid analogue (antilipolytic agent)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isoprenaline infusion (control for dogs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Patients with acute myocardial infarction
Number of subjects: 21
Study: 30268158

Group type: EXPERIMENTAL
Intervention: Low-frequency electrostimulation (ES) administered via CarebandR device on unilateral PC6 acupoint.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Duloxetine or pregabalin prescribed to all participants.
Number of subjects: 80
Study: 27208863

Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 167
Study: 24280031

Group type: EXPERIMENTAL
Intervention: Deep rTMS to bilateral dorsomedial prefrontal cortex (5 Hz, 10‐s train duration, 20‐s inter‐train interval) for 15 min (1500 pulses per session)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Deep rTMS to bilateral dorsomedial prefrontal cortex
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 28
Study: 22951287

Group type: EXPERIMENTAL
Intervention: TAS-102 (35 mg/m² orally twice a day in a 28-day cycle)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 21083880

Group type: EXPERIMENTAL
Intervention: GFU (Glaucoma Follow-up Unit)
Number of subjects: 815

Group type: COMPARATOR
Intervention: Glaucoma specialist group
Number of subjects: 815
Study: 18687253

Group type: EXPERIMENTAL
Intervention: NRTI + efavirenz
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: NRTI + lopinavir/ritonavir
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: efavirenz + lopinavir/ritonavir
Number of subjects: 82
Study: 15903373

Group type: EXPERIMENTAL
Intervention: Lode Excalibur Sport Ergometer
Number of subjects: 26

Group type: COMPARATOR
Intervention: Computrainer
Number of subjects: 26
Study: 12877794

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 197
Study: 11009140

Group type: EXPERIMENTAL
Intervention: 900 mg rifampicin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 600 mg rifampicin
Number of subjects: 126

Group type: COMPARATOR
Intervention: 200 mg doxycycline
Number of subjects: 126

Group type: COMPARATOR
Intervention: Combined regimen (doxycycline with rifampicin)
Number of subjects: 126
Study: 8866630

Group type: EXPERIMENTAL
Intervention: Histamine (1% solution) microinjection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiologic saline microinjection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine (1% solution) combined with oral intake of 20 mg cetirizine
Number of subjects: 0
Study: 1324483

Group type: EXPERIMENTAL
Intervention: Glucomannan fibers (DICOMAN 5:2‐3 gr/die), 2-3 caps twice a day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (30 obese children, aged 5‐18 years)
Number of subjects: 23
Study: 6501718

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 2789